completed

The objective of the POISE-2 study was to determine the impact of clonidine versus placebo and ASA versus placebo on the 30-day risk of all-cause mortality or nonfatal myocardial infarction in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery.

Patients in the POISE-2 trial were randomly assigned to one of four groups:

  • ASA and Clonidine together
  • ASA and Clonidine placebo
  • ASA placebo and Clonidine
  • ASA placebo and Clonidine placebo

Research personnel followed patients at 30 days post-randomization and one year post-randomization.

Primary endpoint:

Composite of all-cause mortality and nonfatal MI at 30 days after randomization.

Study Type

Interventional - Drug

Study Design

Randomized, double-blind, placebo control, factorial assignment

NO. of Countries

34

NO. of Sites

135

NO. of Participants

10010

Study Period

2010-2014

Sponsor

PHRI

Canadian Institutes of Health Research (CIHR)

Back To Top